

Effects of tramadol and dexmedetomidine on recovery in pediatric patients undergoing adenotonsillectomy

Submission date 14/07/2016	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 25/07/2016	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 09/08/2019	Condition category Signs and Symptoms	☐ Individual participant data

Plain English summary of protocol

Background and study aims

An adenotonsillectomy is a common surgical procedure in which the small lumps of tissue at the back of the throat and nose (tonsils and adenoids) are removed. The tonsils and adenoids are part of the immune system they are not essential, and their removal does not damage the immune system in any way. The procedures are very simple and safe, and one of the most common complications is the agitation the child feels when they wake up from general anesthesia (being put to sleep for the operation). This puts a child at risk of hurting themselves, a longer stay in hospital, extra nursing care requirements, the family not being happy with the treatment and increased costs. In order to prevent this problem, giving extra medications as well as the general anesthesia is the standard approach. The aim of this study is to compare the effects of two commonly used drugs on agitation upon waking from general anesthesia (emergence agitation).

Who can participate?

Patients aged between 2-12 years who are having their tonsils and adenoids removed.

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group are given dexmedetomidine (a sedative) mixed with normal saline (salt water) through a drip over a 10 minute period. Those in the second group receive tramadol (a pain-reliever) mixed with normal saline (salt water) through a drip over a 10 minute period. Participants in both groups are put to sleep for their surgery the same way and have their vital signs (such as heart rate, breathing and blood pressure) measured throughout surgery. Participants in both groups are then observed by clinical staff in the recovery area for an hour after their surgery to look for signs of emergence agitation.

What are the possible benefits and risks of participating?

There are no direct benefits or risks involved with taking part in this study.

Where is the study run from?
Gazi University, Medical Faculty (Turkey)

When is the study starting and how long is it expected to run for?
January 2011 to January 2016

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Professor Andrew Hayward
a.hayward@ucl.ac.uk

Contact information

Type(s)
Scientific

Contact name
Prof Nurdan Bedirli

ORCID ID
<https://orcid.org/0000-0003-2624-0259>

Contact details
Gazi University, Medical Faculty
Anesthesiology department
Ankara
Türkiye
06510
+90 5324002824
tip@gazi.edu.tr

Additional identifiers

Protocol serial number
EUEC-2011/135

Study information

Scientific Title
Tramadol vs dexmedetomidine for emergence reaction control in pediatric patients undergoing adenotonsillectomy with sevoflurane anesthesia: Prospective randomised controlled clinical study

Study objectives
The aim of this study is to evaluate the hypothesis that tramadol would control emergence agitation of sevoflurane as efficient as dexmedetomidine in pediatric patients undergoing adenotonsillectomy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Erciyes University Research Ethics Committee, 01/03/2011, ref: 2011/135

Primary study design

Interventional

Study design

Prospective single-centre randomised parallel trial

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Postoperative pain after adenotonsillectomy

Interventions

Patients are randomised to one of two groups according to a computer generated random numbers table.

Group 1: After intubation, patients receive 1 µg/kg dexmedetomidine diluted in saline (2 ml of dexmedetomidine and 8 ml of saline) administered as a single IV dose over a 10 minute period. Group 2: After intubation, patients receive 2 mg/kg tramadol diluted in saline 4 ml of tramadol and 6 ml of saline) administered as a single IV dose over a 10 minute period.

Standard anesthesia monitoring includes electrocardiogram, noninvasive blood pressure, pulse oximetry, and inspiratory and expiratory gas concentrations are applied to all the patients in both group during the surgery. Heart rate (HR), mean arterial pressure (MAP), peripheral oxygen saturation (SpO₂), and minimum alveolar concentration (MAC) are also recorded before induction (baseline), at induction and every 5 minutes after induction during the procedure. After the end of the procedure at the post anesthesia care unit (PACU) the intensity of pain is assessed using a modified Hannallah pain score and observational pain score (OPS), pediatric anesthesia emergence delirium (PAED) scale, Ramsay sedation score (RSS). HR, MAP, SpO₂ are measured and recorded on arrival to PACU and 5, 10, 15, 30, 45, 60 minutes after arrival to PACU. Any adverse effects such as vomiting, airway obstruction, laryngospasm or bronchospasm are also recorded.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

1. Tramadol 2. Dexmedetomidine

Primary outcome(s)

Pain intensity is assessed using a modified Hannallah pain score and observational pain score (OPS), pediatric anesthesia emergence delirium (PAED) scale, Ramsay sedation score (RSS) on arrival to PACU and 5, 10, 15, 30, 45, 60 minutes after arrival to PACU.

Key secondary outcome(s)

1. Heart rate is measured before induction (baseline), at induction and every 5 minutes after induction during the procedure
2. Mean arterial pressure is measured before induction (baseline), at induction and every 5 minutes after induction during the procedure
3. Adverse events are monitored through clinical observations on arrival to PACU and 5, 10, 15, 30, 45, 60 minutes after arrival to PACU

Completion date

01/01/2016

Eligibility

Key inclusion criteria

1. Patients ASA physical status I-II
2. Aged between 2 and 12
3. Undergoing adenotonsillectomy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

2 Years

Upper age limit

12 Years

Sex

All

Total final enrolment

77

Key exclusion criteria

1. Developmental delay
2. Cardiac disorder
3. Psychological disorder
3. Epilepsy
4. Allergy to study medications

Date of first enrolment

01/01/2013

Date of final enrolment

01/01/2015

Locations

Countries of recruitment

Türkiye

Study participating centre

Gazi University, Medical Faculty

Anesthesiology Department

Ankara

Türkiye

06510

Sponsor information

Organisation

Gazi university, Medical Faculty

ROR

<https://ror.org/054xkpr46>

Funder(s)

Funder type

University/education

Funder Name

Gazi University, Medical faculty

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	11/03/2017	09/08/2019	Yes	No